Quick-Med Technologies' NIMBUS(R) Technology Differentiated in Journal Article
July 20 2011 - 8:00AM
Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company
that is developing innovative technologies for the healthcare and
consumer markets, announced today that an article discussing
advantages of NIMBUS antimicrobial technology has been published in
the June 2011 issue of Wound Practice and Research, a prominent
Australian wound care journal. The article is titled "Caution: When
Combining Topical Wound Treatments, More Is Not Always Better" and
describes important and potentially damaging interactions that can
occur between some commonly used wound treatments. As explained by
the senior author, Gregory Schultz, PhD, University of Florida
Research Foundation Professor, "wound care clinicians need to
understand that some combinations of wound dressings and treatments
can destructively interact, reducing their effectiveness, while
other combinations are potentially helpful."
According to the article, BIOGUARD wound dressing is compatible
with Santyl®, a frequently used collagenase debriding agent,
whereas many other dressings deactivate Santyl's active ingredient.
Dressings that were found to have 50% to >90% inhibitory
effect on the Santyl active include those containing silver,
iodine, and PHMB (polyhexamethylene biguanide). BIOGUARD can also
be used with Dakin's Solution®, a popular wound cleanser based on
hypochlorite, while dressings with PHMB such as Kerlix® AMD should
not be used because hypochlorite deactivates the active
antimicrobial agent in the dressing.
"BIOGUARD dressings with NIMBUS antimicrobial technology offer
superior versatility and have been designed to allow worry-free use
in the increasingly complex wound care environment," said Albina
Mikhaylova, PhD, a co-author and Senior Scientist at Quick-Med
Technologies. She explained, "NIMBUS is an important antimicrobial
technology for medical devices because it doesn't leach or suffer
depletion, doesn't initiate bacterial resistance, doesn't interfere
with tissue healing, and prevents odor generation. The article
reports that BIOGUARD can be safely combined with other important
wound treatments."
BIOGUARD® bacterial barrier wound dressings are marketed under
license from Quick-Med by Derma Sciences, Inc. (Nasdaq:DSCI) and
Medline Industries, Inc.
A copy of the article is available on Quick-Med's
website at:
http://content.stockpr.com/qmdt/media/105d792c3b390a1196352dd5586087e0.pdf
About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge
antimicrobial technology that has been custom designed for wound
care and other medical applications. NIMBUS received De Novo
clearance from the U.S. Food and Drug Administration and has been
commercialized in traditional wound care applications. It is the
only non-leaching antimicrobial dressing which, by design, poses no
risk of bacteria developing resistance. NIMBUS technology is
protected by ten U.S. patents and patents pending and 24 foreign
counterparts. Additional applications under development include
advanced wound dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is
developing innovative technologies for the consumer and healthcare
markets. The Company is developing advanced antimicrobial
technologies for infection prevention and control. Its NIMBUS®
technology is the first FDA-cleared, non-leaching antimicrobial
available in a wound dressing. Its NimbuDerm™ technology is being
developed as a persistent hand sanitizer and its new Stay Fresh®
technology provides highly durable antimicrobial protection for
apparel and other textile applications. For more information, see:
www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®
and Stay Fresh® are registered trademarks and NimbuDerm™ is a
trademark of Quick-Med Technologies, Inc. All other trademarks are
property of their respective owners.
Forward-looking statements (statements which are not historical
facts) in this release are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
For this purpose, any statements contained in this release that are
not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as "may", "will", "to", "expect", "plan",
"believe", "anticipate", "intend", "could", "would", "estimate",
and/or "continue" or the negative or other variations thereof or
comparable terminology are intended to identify forward-looking
statements involve risks and uncertainties, including those risks
that are discussed in the Company's filings with the Securities and
Exchange Commission ("SEC"), which may be accessed at the SEC's
Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies, Inc.
J. Ladd Greeno, CEO
(888) 835.2211 Ext 102
lgreeno@quickmedtech.com
Stonegate Securities, Inc.
Casey Stegman (investor/media contact)
(214) 987-4121
casey@stonegateinc.com
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From May 2023 to May 2024